Literature DB >> 21097605

Myocardial parvovirus B19 persistence: lack of association with clinicopathologic phenotype in adults with heart failure.

Garrick C Stewart1, Javier Lopez-Molina, Raju V S R K Gottumukkala, Gregg F Rosner, Mary S Anello, Jonathan L Hecht, Gayle L Winters, Robert F Padera, Kenneth L Baughman, Myra A Lipes.   

Abstract

BACKGROUND: Multiple viruses have been isolated from the heart, but their significance remains controversial. We sought to determine the prevalence of cardiotropic viruses in endomyocardial biopsy (EMB) samples from adult patients with heart failure (HF) and to define the clinicopathologic profile of patients exhibiting viral positivity. METHODS AND
RESULTS: EMB from 100 patients (median ejection fraction, 30%; interquartile range [IQR], 20% to 45%) presenting for cardiomyopathy evaluation (median symptom duration, 5 months; IQR, 1 to 13 months) were analyzed by polymerase chain reaction for adenovirus, cytomegalovirus, enteroviruses, Epstein-Barr virus, and parvovirus B19. Each isolate was sequenced, and viral load was determined. Parvovirus B19 was the only virus detected in EMB samples (12% of subjects). No patient had antiparvovirus IgM antibodies, but all had IgG antibodies, suggesting viral persistence. The clinical presentation of parvovirus-positive patients was markedly heterogeneous with both acute and chronic HF, variable ventricular function, and ischemic cardiomyopathy. No patient met Dallas histopathologic criteria for active or borderline myocarditis. Two patients with a positive cardiac MRI and presumed "parvomyocarditis" had similar viral loads to autopsy controls without heart disease. The oldest parvovirus-positive patients were positive for genotype 2, suggesting lifelong persistence in the myocardium.
CONCLUSIONS: Parvovirus B19 was the only virus isolated from EMB samples in this series of adult patients with HF from the United States. Positivity was associated with a wide array of clinical presentations and HF phenotypes. Our studies do not support a causative role for parvovirus B19 persistence in HF and, therefore, advocate against the use of antiviral therapy for these patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21097605      PMCID: PMC3047418          DOI: 10.1161/CIRCHEARTFAILURE.110.958249

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  35 in total

1.  The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology.

Authors:  Leslie T Cooper; Kenneth L Baughman; Arthur M Feldman; Andrea Frustaci; Mariell Jessup; Uwe Kuhl; Glenn N Levine; Jagat Narula; Randall C Starling; Jeffrey Towbin; Renu Virmani
Journal:  Circulation       Date:  2007-10-24       Impact factor: 29.690

2.  Viral persistence in the myocardium is associated with progressive cardiac dysfunction.

Authors:  Uwe Kühl; Matthias Pauschinger; Bettina Seeberg; Dirk Lassner; Michel Noutsias; Wolfgang Poller; Heinz-Peter Schultheiss
Journal:  Circulation       Date:  2005-09-19       Impact factor: 29.690

3.  High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction.

Authors:  Uwe Kühl; Matthias Pauschinger; Michel Noutsias; Bettina Seeberg; Thomas Bock; Dirk Lassner; Wolfgang Poller; Reinhard Kandolf; Heinz-Peter Schultheiss
Journal:  Circulation       Date:  2005-02-07       Impact factor: 29.690

4.  Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue.

Authors:  Päivi Norja; Kati Hokynar; Leena-Maija Aaltonen; Renwei Chen; Annamari Ranki; Esa K Partio; Olli Kiviluoto; Irja Davidkin; Tomi Leivo; Anna Maria Eis-Hübinger; Beate Schneider; Hans-Peter Fischer; René Tolba; Olli Vapalahti; Antti Vaheri; Maria Söderlund-Venermo; Klaus Hedman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

5.  Tissue persistence of parvovirus B19 genotypes in asymptomatic persons.

Authors:  Fabiana Corcioli; Krystyna Zakrzewska; Alessio Rinieri; Rosa Fanci; Massimo Innocenti; Roberto Civinini; Vincenzo De Giorgi; Simonetta Di Lollo; Alberta Azzi
Journal:  J Med Virol       Date:  2008-11       Impact factor: 2.327

6.  Parvovirus B19 profiles in patients presenting with acute myocarditis and chronic dilated cardiomyopathy.

Authors:  Felicitas Escher; Susanne Modrow; Titus Sabi; Uwe Kühl; Dirk Lassner; Heinz-Peter Schultheiss; Michel Noutsias
Journal:  Med Sci Monit       Date:  2008-12

7.  Cardiovascular magnetic resonance in myocarditis: A JACC White Paper.

Authors:  Matthias G Friedrich; Udo Sechtem; Jeanette Schulz-Menger; Godtfred Holmvang; Pauline Alakija; Leslie T Cooper; James A White; Hassan Abdel-Aty; Matthias Gutberlet; Sanjay Prasad; Anthony Aletras; Jean-Pierre Laissy; Ian Paterson; Neil G Filipchuk; Andreas Kumar; Matthias Pauschinger; Peter Liu
Journal:  J Am Coll Cardiol       Date:  2009-04-28       Impact factor: 24.094

8.  Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis.

Authors:  Friedhelm Kuethe; Juha Lindner; Klaus Matschke; Juergen J Wenzel; Päivi Norja; Katrin Ploetze; Sarah Schaal; Virginia Kamvissi; Stefan R Bornstein; Uta Schwanebeck; Susanne Modrow
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

9.  Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy.

Authors:  U Kühl; D Lassner; M Pauschinger; U M Gross; B Seeberg; M Noutsias; W Poller; H-P Schultheiss
Journal:  J Med Virol       Date:  2008-07       Impact factor: 2.327

10.  High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy.

Authors:  Thomas Schenk; Martin Enders; Stefan Pollak; Ralph Hahn; Daniela Huzly
Journal:  J Clin Microbiol       Date:  2008-11-12       Impact factor: 5.948

View more
  24 in total

1.  Myocardial infarction triggers chronic cardiac autoimmunity in type 1 diabetes.

Authors:  Raju V S R K Gottumukkala; HuiJuan Lv; Lizbeth Cornivelli; Amy J Wagers; Raymond Y Kwong; Roderick Bronson; Garrick C Stewart; P Christian Schulze; William Chutkow; Howard A Wolpert; Richard T Lee; Myra A Lipes
Journal:  Sci Transl Med       Date:  2012-06-13       Impact factor: 17.956

Review 2.  Role of impaired central tolerance to α-myosin in inflammatory heart disease.

Authors:  HuiJuan Lv; Myra A Lipes
Journal:  Trends Cardiovasc Med       Date:  2012-08-16       Impact factor: 6.677

Review 3.  Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy.

Authors:  B Maisch; S Pankuweit
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

4.  Diagnostic and prognostic validity of different biomarkers in patients with suspected myocarditis.

Authors:  Christian Ukena; Michael Kindermann; Felix Mahfoud; Jürgen Geisel; Philipp M Lepper; Reinhard Kandolf; Michael Böhm; Ingrid Kindermann
Journal:  Clin Res Cardiol       Date:  2014-04-30       Impact factor: 5.460

5.  Predictors of outcome in patients with parvovirus B19 positive endomyocardial biopsy.

Authors:  Simon Greulich; Ingrid Kindermann; Julia Schumm; Andrea Perne; Stefan Birkmeier; Stefan Grün; Peter Ong; Tim Schäufele; Karin Klingel; Steffen Schneider; Reinhard Kandolf; Michael Böhm; Udo Sechtem; Heiko Mahrholdt
Journal:  Clin Res Cardiol       Date:  2015-07-02       Impact factor: 5.460

6.  Impaired thymic tolerance to α-myosin directs autoimmunity to the heart in mice and humans.

Authors:  Huijuan Lv; Evis Havari; Sheena Pinto; Raju V S R K Gottumukkala; Lizbeth Cornivelli; Khadir Raddassi; Takashi Matsui; Anthony Rosenzweig; Roderick T Bronson; Ross Smith; Anne L Fletcher; Shannon J Turley; Kai Wucherpfennig; Bruno Kyewski; Myra A Lipes
Journal:  J Clin Invest       Date:  2011-03-23       Impact factor: 14.808

Review 7.  Classification and histological, immunohistochemical, and molecular diagnosis of inflammatory myocardial disease.

Authors:  Cristina Basso; Fiorella Calabrese; Annalisa Angelini; Elisa Carturan; Gaetano Thiene
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

Review 8.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

Review 9.  Viral myocarditis: from experimental models to molecular diagnosis in patients.

Authors:  Sabine Pankuweit; Karin Klingel
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

Review 10.  Peripartum cardiomyopathy: A puzzle closer to solution.

Authors:  James D Fett
Journal:  World J Cardiol       Date:  2014-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.